Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EFPIA laments 'unfortunate' WHO decision on Lucentis

This article was originally published in SRA

Executive Summary

The World Health Organization's "unprecedented" decision not to put Novartis's Lucentis on its essential medicines list (EML) for wet AMD, while retaining an unlicensed drug (Roche's Avastin) on the list, sends out a "very unfortunate signal" to industry and regulators, says Richard Bergström, director general of the European industry federation EFPIA.

You may also be interested in...



Another Knockback For Roche And Novartis As CJEU Rules On Italian Competition Case

In the latest development in the long-running case pitting Novartis and Roche against the Italian competition authority over a fine imposed in 2014, the Court of Justice of the EU has confirmed that the firms’ arrangement over Avastin and Lucentis could constitute a serious restriction on competition if it involved the dissemination of misleading information. The case now goes back to the Italian court.

Three Major Regulators Launch Pilot To Reduce Duplication Of GMP Inspections

Regulatory bodies from Australia, Canada and the UK say a new pilot program will reduce the need for multiple inspections of the same site, while an MoU signed by Australia and Canada will cut the amount of documentary evidence required from drug sponsors seeking GMP clearances. 

European Parliament Supports Explicit Patent Linkage Ban

An explicit ban on patent linkage would ensure that competition to originator drugs is not delayed, according to off-patent industry group Medicines for Europe.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel